ESMO Congress | Conference

COVID-19 Crisis Results in Increased Risk of Distress, Burnout Among Oncology Professionals

September 13th 2020

The wellbeing and job performance of oncology professionals has been significantly impacted by the COVID-19 pandemic, and although the extent of this impact is varied between countries, it has been suggested to be related to the crude mortality rate of the virus.

Olaparib/Durvalumab Combo Shows Promising Long-Term Activity in Germline BRCA+ Breast, Ovarian Cancer

October 8th 2019

Updated results from the phase I/II MEDIOLA study strengthen the case for combining olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations. The updated data were featured in two separate presentations at the 2019 ESMO Congress.

Nivolumab/Tivozanib Combo Shows Promise in mRCC

October 8th 2019

Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.

Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC

October 7th 2019

Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.

Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers

October 4th 2019

Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.

Ripretinib Shows Dramatic PFS Improvement for Heavily Pretreated GIST

October 4th 2019

Treatment with the novel KIT and PDGFRA inhibitor ripretinib reduced the risk of progression or death by 85% compared with placebo for heavily pretreated patients with advanced gastrointestinal stromal tumors, according to findings from the phase III INVICTUS trial presented at the ESMO Congress 2019.

Trametinib Emerges as New Standard Option for Recurrent, Low-Grade Ovarian Cancer

October 4th 2019

Treatment with the MEK inhibitor trametinib significantly improves progression-free survival and leads to a strong trend toward improved overall survival in recurrent, low-grade serous ovarian cancer.

Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer

October 3rd 2019

Durvalumab added to etoposide and platinum-based chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer delays development of new lesions and improves patient-reported outcomes compared with etoposide and platinum-based therapy alone.

Entrectinib Delivers Durable Responses in ROS1+, NTRK+ Lung Cancer

October 3rd 2019

Patients with ROS1-positive and NTRK-positive non–small cell lung cancer had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib.

Nivolumab/Ipilimumab Combo Delivers Durable Clinical Activity in Cervical Cancer

October 1st 2019

The combination of nivolumab and ipilimumab appears to have durable clinical activity in patients with recurrent or metastatic cervical cancer.

Cabazitaxel Emerges as Third-Line Standard for Metastatic CRPC

October 1st 2019

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

Nivolumab Improves Survival in Advanced Esophageal Cancer

October 1st 2019

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.

Pembrolizumab Misses PFS Endpoint in Relapsed Malignant Pleural Mesothelioma

September 30th 2019

Pembrolizumab (Keytruda) did not show an improvement in progression-free survival compared with chemotherapy in patients with malignant pleural mesothelioma.

Case Series Highlights Afatinib Activity in NRG1+ Cancers

September 30th 2019

A case series presented at the 2019 ESMO Congress highlighted the activity of afatinib in patients with NRG1-positive tumors.

Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer

September 30th 2019

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer

September 30th 2019

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

ClarIDHy Ivosidenib Data Practice-Changing for Advanced Cholangiocarcinoma

September 30th 2019

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC

September 30th 2019

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

Larotrectinib Continues to Show High Efficacy, Low Toxicity in TRK Fusion-Positive Cancers

September 29th 2019

The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.

Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer

September 29th 2019

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.